Results 221 to 230 of about 708,936 (290)
Med Research, EarlyView.This review summarizes the immuno‐inflammatory mechanisms driving the pathogenesis of osteoarthritis (OA), extending beyond the traditional view of OA as a purely degenerative disease to incorporate immune cell infiltration, inflammatory factor release, and the formation of a chronic low‐grade inflammatory microenvironment.
Qingqiang Lei +9 more
wiley +1 more source
Phenotypic Clues in Infantile‐Onset Parkinsonism‐Dystonia‐2: A Treatable Neurotransmitter Disorder
Movement Disorders Clinical Practice, EarlyView.
Sangeetha Yoganathan +10 more
wiley +1 more source
Altered Cerebrospinal Fluid Tryptophan–Kynurenine Pathway Metabolism in Multiple System Atrophy
Movement Disorders, EarlyView.Abstract Background Alterations in tryptophan–kynurenine (TRP‐KYN) metabolism, which is associated with neuroinflammation, remain unclear in multiple system atrophy (MSA). Objective The aim was to investigate cerebrospinal fluid (CSF) TRP metabolites in MSA and their associations with other biomarkers.
Ryunosuke Nagao +8 more
wiley +1 more source
Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study
Movement Disorders, EarlyView.Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri +13 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background Intracerebral gene therapy is effective for amino acid decarboxylase (AADC) deficiency, but relationships between anatomical putaminal coverage, metabolic dynamics, and clinical recovery remain poorly understood. Objectives Assess safety, long‐term efficacy, and clinical–radiological correlations in a genetically diverse European ...
Clément Dunoyer +27 more
wiley +1 more source
Movement Disorders, EarlyView.Abstract Background There is a lack of treatments for non‐motor symptoms (NMS) in Parkinson's disease (PD). Objective To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. Methods This phase II, randomized, placebo‐controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9 ...
Gabriel T. Kubota +14 more
wiley +1 more source
COVID‐19 Amplifies Sex‐Specific Dopamine and Glial Responses in a Parkinson's Disease Mouse Model
Movement Disorders, EarlyView.Abstract Background Exposure to environmental agents, including viral infections, may increase Parkinson's disease (PD) susceptibility, especially in males, but the neurodegenerative risk extent of COVID‐19 remains uncertain. Objectives We investigated the plausible link between severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and
Ifeoluwa Awogbindin +10 more
wiley +1 more source